GLP-1激动剂的竞争文化话语:关系辩证理论的应用
Maggie A Unruh1, Charee M Thompson1
1Department of Communication, University of Illinois Urbana-Champaign, Urbana, IL, USA.
Qualitative health research
|April 28, 2025
概括
类似葡萄糖-1 (GLP-1) 的体重管理药物被认为是通过竞争的社会话语,导致用户的双重污名化. 这项研究探讨了这些复杂的观点及其对个人的影响.
科学领域:
- 健康和疾病的社会学
- 医学话语分析 医学话语分析
- 体重管理的社会心理学
背景情况:
- 葡萄糖类-1 (GLP-1) 药物日益普及,加剧了围绕其用于减肥和管理的公共话语.
- 体重管理经常被视为个人责任,强调个人选择和行为.
- 关系辩证理论强调了支配性和边缘化话语在塑造社会意义上的动态相互作用.
研究的目的:
- 检查围绕使用GLP-1药物用于体重管理的竞争性话语.
- 通过关系辩证理论的透视来分析这些话语.
- 了解使用或考虑使用GLP-1药物来控制体重的个体的生活经验.
主要方法:
- 进行了一项定性在线调查,对130名参与者进行了调查,他们曾使用过,考虑过或目前正在使用GLP-1药物来控制体重.
- 使用反点分析来检查所识别的话语.
- 该研究的重点是了解GLP-1药物使用所产生的社会和个人意义.
主要成果:
- 确定了四种主导性话语:GLP-1s作为"神奇的子弹"或"快速修复",关于"值得"的问题,GLP-1s作为"自由和控制",GLP-1s作为"医学上必要".
- 这些话语的相互作用揭示了围绕GLP-1药物使用的复杂社会格局.
- 用GLP-1药物来控制体重的个人经历了双重的耻辱,无论是因为他们的体重还是他们选择的管理方法.
结论:
- 用GLP-1药物来控制体重的使用受到重大的社会审查和相互竞争的叙述.
- 使用这些药物的个人面临着双重的耻辱,使他们的体重管理之旅复杂化.
- 主导的社会话语创造了一个环境,逃避与体重相关的耻辱及其管理对GLP-1用户来说是具有挑战性的.
相关概念视频
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Oral Hypoglycemic Agents: Glinides
109
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
106
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
106
Hormonal Regulation
42.9K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
42.9K
Agonism and Antagonism: Quantification
254
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
254
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117


